Open Access Mini Review

Thrombolysis: The Current State of The Art and How it can be Improved

Victor Gurewich*

Department of Medicine, USA

Corresponding Author

Received Date: April 26, 2019;  Published Date: May 03, 2019


Current thrombolytic therapy is essentially synonymous with high dose tPA administered iv for 90 minutes. This treatment has had only limited success in acute myocardial infarction (AMI) [1-3], and consequently has more recently been replaced by percutaneous coronary intervention (PCI) as the treatment of choice in AMI [4]. Although PCI delays coronary reperfusion, better clinical outcomes than with tPA were nevertheless obtained [5]. In the treatment of ischemic stroke, a tPA dose reduction was required due to a 20% intracranial hemorrhage (ICH) incidence when the AMI dose was used [6].

Signup for Newsletter
Scroll to Top